Phathom Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
PHAT$5.25+3.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Deficit
(in thousands, except share amounts)
| Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Capital | Deficit | Deficit | |
| Balance at December 31, 2023 | 57,970,044 | $5 | 19 | $855,921 | $(928,685) | $(72,759) |
| 401(k) matching contribution | 383,589 | — | — | 3,683 | — | 3,683 |
| Vesting of restricted stock units | 965,681 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 24,047 | — | 24,047 |
| ESPP shares issued | 375,381 | — | — | 2,401 | — | 2,401 |
| Issuance of common stock from exercises of stock options | 127,891 | — | — | 1,599 | — | 1,599 |
| Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net | 8,695,652 | 1 | — | 121,774 | — | 121,775 |
| Net loss | — | — | — | — | (334,326) | (334,326) |
| Balance at December 31, 2024 | 68,518,238 | $6 | 19 | $1,009,425 | $(1,263,011) | $(253,580) |
| Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Capital | Deficit | Deficit | |
| Balance at December 31, 2022 | 41,468,871 | $3 | 19 | $652,276 | $(727,093) | $(74,814) |
| 401(k) matching contribution | 135,956 | — | — | 1,612 | — | 1,612 |
| Vesting of restricted shares, performance stock units, and restricted stock units | 1,843,954 | — | — | 6 | — | 6 |
| Stock-based compensation | — | — | — | 45,025 | — | 45,025 |
| ESPP shares issued | 196,873 | — | — | 1,417 | — | 1,417 |
| Issuance of common stock under ATM facility | 1,514,219 | 1 | — | 14,072 | — | 14,073 |
| Issuance of common stock from exercises of stock options | 16,421 | — | — | 124 | — | 124 |
| Issuance of common stock in connection with underwritten public offering, net | 12,793,750 | 1 | — | 141,389 | — | 141,390 |
| Net loss | — | — | — | — | (201,592) | (201,592) |
| Balance at December 31, 2023 | 57,970,044 | $5 | 19 | $855,921 | $(928,685) | $(72,759) |
See accompanying notes
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.